Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs

This article was originally published in RPM Report

Executive Summary

FDA announced February 4 that it is undergoing a “far-reaching action plan” to assess its approach to opioid medications in a bid to resolve one of the final obstacles blocking confirmation of Robert Califf as FDA Commissioner.

Advertisement

Related Content

A Fitting Farewell: Hamburg Earns Praise From Rep. Rogers In Final Approps Hearing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register